INDEX OF SUBJECTS FOR VOLUME 39

Abscess
  bactericidal lipids in, 58
  host response to coagulase-negative staphylocci, 191
  pathogenicity of co-aggregated oral bacteria, 183
  survival of *S. aureus* in, 58
Acanthamoeba
  in contact lens-associated keratitis, 1
Actinomyces viscosus
  co-aggregation with *S. mitis*, 183
  phagocytosis by PMNLs, 183
Adherence
  E. coli to cell culture, 371
  P. aeruginosa to epithelial cells, 401, 403
  pili of *N. meningitidis*, 7
  properties of *B. bronchiseptica*, 388
  S. aureus to cell monolayers, 422
  S. bovis to buccal epithelial cells, 53
Aeromonas
  A. hydrophila, metallo-β-lactamase, 93
  carbapenem resistance, 93
  characterisation of strains, 107
  epidemiological markers, 107
  metallo-β-lactamases, 93
  typing by immunoblotting, 325
Agglutination
  co-agglutination assay for *S. typhi*, 74
Alphavirus, pathogenesis *in vitro*, 26
Ampicillin, and expression of *E. coli* LPS, 100
Anaerobes
  fusobacteria, and disease in man, 246
  fusobacteria, new taxonomy, 246
  hydrogen peroxide production by oral streptococci, 429
  see also Bacteroides
Antibiotic resistance
  carbapenems, and *Aeromonas* spp., 93
  carbapenems and *S. marcescens*, 93
  erythromycin, and *S. pyogenes*, 165
  and metallo-β-lactamases, 93
  methicillin, and *S. aureus*, 422
  multiresistance of *S. typhi*, 454
  rifampicin, and *N. meningitidis*, 15
  sulphonamides, and *N. meningitidis*, 15
  teicoplanin, and *S. epidermidis*, 204
  ultrastructural studies of *S. epidermidis*, 204
  vancomycin, and *S. epidermidis*, 204
Antibiotics and other antimicrobial substances
  and binding of *E. coli* LPS by monoclonal antibodies, 100
  chemoprophylaxis of meningococcal disease, 15
  flow cytometry studies of bacterial responses, 147
  in fusobacteria infection, 246
  modes of action against *E. coli*, 147
  subinhibitory levels, and expression of *E. coli* LPS, 100
  susceptibility of *C. difficile*, 345
  susceptibility of *Edwardsiella* spp., 273
Antibodies
  against *B. abortus*, 403
  against *B. burgdorferi*, 290
  against hepatitis C virus, 321, 323
  against *N. meningitidis*, 4, 7, 9, 17
  against *P. aeruginosa*, 459, 465
  against *P. cepacia*, 39
  against *V. cholerae*, 135
  against verocytotoxigenic *E. coli*, 408
  against *Yersinia* spp., 268
  and synthetic peptide vaccines, 241
  see also Monoclonal antibodies
Antigens
  of *B. abortus*, 403
  of *B. burgdorferi*, 290
  expression and binding of *E. coli* LPS, 100
  of hepatitis B virus, 473
  of hepatitis C virus, 323
  hydatid, 48
  of *N. meningitidis*, 3, 4, 9, 17
  of *P. aeruginosa*, 459
  of *P. cepacia* in cystic fibrosis, 39
  of *P. shigelloides*, 211
  of *S. pyogenes*, 165
  of *S. typhi*, in co-agglutination assay, 74
  in synthetic peptide vaccines, 241
  outer-membrane, of *V. cholerae*, 135
Antiserum
  against *Aeromonas* spp., 325
  against *B. melitensis*, 363
Antitoxin therapy, and *C. botulinum*, 243
API system, 78
Aspergillus fumigatus, alkaline protease, 393

Bacillus
  B. cereus, metallo-β-lactamase, 93
Bacteroides
  B. distasonis, metallo-β-lactamase, 93
  B. fragilis, carbapenem resistance, 93
  B. fragilis, metallo-β-lactamase, 93
  B. fragilis, plasmid, 93
  carbapenem resistance, 93
  metallo-β-lactamases, 93
Blood culture
  detection of *S. aureus*, 128
  detection of *S. typhi*, 74
Blood donors, 321, 323
Blood transfusions, 321, 323
BOOKS RECEIVED
  Candidiasis. Pathogenesis, Diagnosis and Treatment, 2nd edition (Edited by G. P. Bodey), 240
  Cowan and Steel's Manual for the Identification of Medical Bacteria, 3rd edition (Edited by G. I. Barrow and R. K. A. Feltham), 319
  Current Topics in Microbiology and Immunology. ADP-Ribosylating Toxins (Edited by K. Aktories), 80
  Developments in Biological Standardization, Volume 76. Continuous Cell Lines—An International Workshop on Current Issues (Edited by the International Association of Biological Standardization), 92
  Diagnostic Immunology (D. F. Keren and J. S. Warren), 320
  Hospital Infection Control (S. Mehtar), 92
  Medical Microbiology, 14th edition. A Guide to Microbial Infections: Pathogenesis, Immunity, Laboratory Diagnosis and Control (Edited by D. Greenwood, R. Slack and J. Peutherer), 92
  Microbes and Man, 3rd edition (Edited by J. Postgate), 240
  Molecular Biology of Bacterial Infection. Current Status and Future Perspectives (Edited by C. E. Hormaeche, C. W. Penn and C. J. Smyth), 478
  Molecular and Cell Biology of Sexually Transmitted Diseases (Edited by D. Wright and L. Archard), 320
  Mycoplasmas. Molecular Biology and Pathogenesis (Edited by J. Maniloff, R. N. McElhaney, L. R. Finch and J. B. Baseman), 319
  Pharmaceutical Microbiology, 5th edition (Edited by W. B. Hugo and A. D. Russell), 240
  Prion Diseases of Humans and Animals (Edited by S. B. Brusiner, J. Collinge, J. Powell and B. Anderton), 478
  Progress in Medical Virology (Edited by J. L. Melnick), 320
  The Staphylococci (Edited by J. Jeljaszewicz and P. Ciborowski), 478
Bordetella
  B. bronchiseptica, adherence, 388
  B. bronchiseptica, haemagglutinin, 388
  B. pertussis, cell-mediated response to infection, 163
  B. pertussis, vaccine, 163
Borrelia burgdorferi
  flagellin, 290
  intrathecal synthesis of antibodies, 290
Botulism, 243

Brevibacterium
new species: *B. mcbrellneri*, 255
synergy with *T. beigelii* in white piedra, 255
Brucella
B. abortus, antibody response in infection, 403
B. abortus, outer-membrane proteins, 403
B. melitensis, lipopolysaccharide expression, 363
B. melitensis, smooth and rough phase properties, 363
Brucellosis, diagnosis of, 403

Candida albicans
diagnosis of candidosis, 233
heat shock protein gene, 233
Capsule, of *N. meningitidis*, 3, 4, 9, 17
Carbapenem resistance
and *Aeromonas* spp., 93
and *Bacteroides* spp., 93
and metallo-β-lactamases, 93
and *S. marcescens*, 93
and *X. maltophilia*, 93
Ceftriaxone, and meningococcal disease, 15
Cell culture
adherence of *E. coli*, 371
adherence of *P. aeruginosa* to epithelial cells, 459, 465
adherence properties of *B. bronchiseptica*, 388
adherence of *S. aureus*, 422
pathogenesis of Semliki Forest virus in endothelial cells, 26
Chemiluminescence, 196
Chloramphenicol, effects on expression of *E. coli* LPS, 100
Chromatography
affinity, 388
gas, 371
high-performance liquid, 262
negative affinity, 465
protein A-sepharose, 465
Ciprofloxacin
effects on expression of *E. coli* LPS, 100
in meningococcal disease, 15
Clostridia
C. botulinum, in sudden infant death syndrome, 114
C. botulinum, toxins, 114, 243
C. difficile, antimicrobial susceptibility, 345
C. difficile, nosocomial outbreak, 345
C. difficile, in sudden infant death syndrome, 114
C. difficile, toxin, 114
C. difficile, typing by pyrolysis mass spectrometry, 345
C. perfringens, in sudden infant death syndrome, 114
C. perfringens, toxins, 114
Complement
activation, in meningococcal disease, 9
fixation tests, and human hydatid disease, 48
Contact lenses, and the microbiologist, 1
Culture media
hydrogen peroxide production by oral streptococci, 429
selective, for verocytotoxigenic *E. coli*, 155
transport system for *H. pylori*, 334
Cystic fibrosis, 39, 459, 465
Cytotoxins
of *C. difficile*, 114
of *E. coli*, 155, 408

Diarrhoea
P. shigelloides infection, 211
V. cholerae infection, 310
DNA
detection of *C. albicans* by PCR, 233
detection of *H. pylori* by PCR, 338
detection of human papillomavirus by PCR, 33
detection of *M. leprae* by PCR, 298
genotypic typing of *Salmonella* serotype Enteritidis, 446
hybridisation, 233, 298, 352, 416, 446, 454, 473
phenotypic loss of protein A production by *S. aureus*, 422
probes for detection of hepatitis B virus, 473
random amplified polymorphic DNA (RAPD) typing, 161
restriction analysis, 33, 416, 429
typing of *P. gingivalis* by PCR, 416

Echinococcus granulosus, screening for human hydatid disease, 48
Edwardsiella spp.
antimicrobial susceptibility, 273
β-lactamase production, 273
plasmid analysis, 273
serum resistance, 273
Electronmicroscopy
antibiotic resistance of *S. epidermidis*, 204
immuno-electronmicroscopy, 393
synthesis of alkaline protease by *A. fumigatus*, 393
transmission, 204
Electrophoresis
multilocus enzyme (MLEE), 3, 4
pulsed-field gel, 446
see also SDS–PAGE
ELISA
antibodies against *P. cepacia*, 39
antibody response to *B. abortus*, 403
antibody response to *V. cholerae* antigens, 135
detection of *S. aureus*, 128
diagnosis of *B. burgdorferi* infection, 290
IgG response to *P. aeruginosa*, 465
sandwich method (sELISA), 128
screening for hydatid disease, 48
Endocarditis, infective, 179
Endotoxin
of *E. coli*, in urinary infection, 69
of *N. meningitidis*, 3
Enterotoxins
of *C. difficile*, 114
of *C. perfringens*, 114
of *S. aureus*, 114
in sudden infant death syndrome, 114
Enzyme immunoassay (EIA)
antibodies to yersinia outer-membrane proteins, 268
diagnosis of hepatitis C virus infection, 323
diagnosis of verocytoxigenic *E. coli*, 408
Enzyme-linked immunofiltration assay, sandwich (sELIFA), 128
Enzyme-linked immunosorbent assay *see* ELISA
Epidemiology
Aeromonas spp., 107
β-haemolytic streptococci, 440
hepatitis C virus, 323
meningococcal disease, 3
nosocomial outbreak of *C. difficile*, 345
S. typhi, 454
Salmonella serotype Enteritidis, 446
screening for hydatid disease by ELISA, 48
transmission of *P. gingivalis*, 416
typing by random amplification of polymorphic DNA, 161
Erythromycin resistance, of *S. pyogenes*, 165
Escherichia coli
adherence, 371
antibodies in haemorrhagic colitis, 408
cysteine-requiring, 382
effect of antibiotics of LPS expression, 100
endotoxin, 69
exopolysaccharide, 371
modes of action of antibiotics, 147
monoclonal antibodies, 100
outer-membrane proteins, 371
phagocytosis and killing by PMNLs in urine, 69
pilli, 371
plasmid, 371
selective medium, 155
verocytotoxin-producing, 155, 408
Exopolysaccharide, of *E. coli*, 371
Exotoxins
exotoxin A of *P. aeruginosa*, 141

Faeces
cysteine-requiring *E. coli* isolates, 382
cysteine-requiring *Klebsiella* isolates, 382
enterotoxigenic bacteria in sudden infant death syndrome, 114
faecal antibodies in *E. coli* infection, 408
Fatty acid
bactericidal, 58
modifying enzyme (FAME), 191

Flagellin, of *B. burgdorferi*, 290
Flow cytometry, bacterial responses to antibiotics, 147
Fluoroquinolones, in meningococcal disease, 15
Foot and mouth disease virus, 241
Fusobacteria
  antibiotic therapy, 246
  characterisation, 246
  laboratory diagnosis, 246
  new taxonomy, 246
  related diseases in man, 246

Gastric biopsy, 334, 338
Gastric mucosa
  inflammatory response to "*G. suis*", 64
Gastritis
  mouse model, 64
  spiral bacteria-associated, 64
"*Gastrospirillum suis*"
  inflammatory response of gastric mucosa, 64
Gene conversion: variant pili of *N. meningitidis*, 7
Gentamicin, effects on expression of *E. coli* LPS, 100
Glasgow Meningococcal Septicaemia Prognostic Score, 11
Glomerulonephritis, acute post-streptococcal, 165

Haemagglutinin, of *B. bronchiseptica*, 388
Haemolysin, of *P. penneri*, 282
Haemophilus
  H. influenzae, transferrin-binding properties, 218
  H. parahaemolyticus, transferrin-binding properties, 218
  H. parainfluenzae, porphyrin production, 262
  H. parainfluenzae, transferrin-binding properties, 218
  misidentification in API system, 78
Haemorrhagic colitis, 408
Helicobacter pylori
  detection by polymerase chain reaction, 338
  transport system for cultures, 334
  urease C gene, 338
Hepatitis B virus
  antigen, 473
  detection in serum, 473
Hepatitis C virus
  epidemiology, 323
  serological diagnosis, 323
  treatment and prognosis, 321
Historical review, 87
Hybridisation of DNA
  detection of *C. albicans*, 233
  detection of hepatitis B virus, 473
  detection of *M. leprae* by PCR, 298
  detection of oral viridans streptococci, 352
  genotypic typing of *Salmonella* serotype Enteritidis, 446
  typing of *P. gingivalis*, 416
  typing of *S. typhi*, 454
Hydatid disease, 48
Hydrogen peroxide
  production by oral streptococci, 429

Imipenem resistance
  and *Bacteroides* spp., 93
  and metallo-β-lactamases, 93
  and *S. marcescens*, 93
  and *X. maltophilia*, 93
Immune response
  and *B. burgdorferi*, 290
  and *B. pertussis*, 163
  cystic fibrosis patients and *P. cepacia*, 39
  and *N. meningitidis*, 9
  and *P. aeruginosa*, 459, 465
  and *P. mirabilis*, 225
  and synthetic peptide vaccines, 241
  and *V. cholerae* outer-membrane antigens, 135
Immunisation
  against *N. meningitidis*, 17
  mice against *B. pertussis*, 163
Immunoblotting
  characterisation of *B. melitensis*, 363
  detection of hepatitis C virus, 323
  exoproteins of *S. intermedius*, 429
  IgG response to *V. cholerae* antigens, 135
  immune response to *P. cepacia*, 39
  recombinant immunoblot assay (RIBA), 323
  typing system for *Aeromonas* spp., 325
Immunoglobulins
  cleavage of IgG by *P. mirabilis*, 225
  IgA, against verocytotoxigenic *E. coli*, 408
  IgA response to *P. cepacia*, 39
  IgG, against verocytotoxigenic *E. coli*, 408
  IgG, in *B. burgdorferi* infection, 290
  IgG response to *P. aeruginosa*, 459, 465
  IgG response to *P. cepacia*, 39
  IgG response to *V. cholerae*, 135
  IgM, in *B. burgdorferi* infection, 290
  induced in meningococcal disease, 9
Immunoturbidimetric assay, 363
Inflammatory response
  gastric mucosa to "*G. suis*", 64
Influenza virus, 241
Interferons: alpha-interferons, 321
Iron
  transferrin-binding properties of *Haemophilus* spp., 218

Kawasaki disease, 352
Keratitis, contact lens-associated, 1
Klebsiella, cysteine-requiring, 382

β-Lactamase
  metallo-β-lactamases, 93
  production by *Edwardsiella* spp., 273
Lectin typing
  β-haemolytic streptococci, 440
  S. aureus, 305
Leprosy, 298
Lipids, bactericidal
  in abscesses, 58
  sensitivity of *S. aureus*, 58
Lipo-oligosaccharide (LOS), of *N. meningitidis*, 3, 9, 17
Lipopolysaccharide (LPS)
  antigens of *P. cepacia*, 39
  of *B. abortus*, 403
  of *B. melitensis*, 363
  of *E. coli*, 100
Lipoteichoic acids
  in adherence of *S. bovis*, 53
  extracellular, of viridans streptococci, 352
Liver transplantation, 321
Lyme neuroborreliosis, 290

Malaria, vaccine against, 241
Media *see* Culture media
Meningitis, 3, 246
  streptococcal, 165
  see also Neisseria meningitidis
Meningococcal disease *see Neisseria meningitidis*
Meropenem resistance
  and metallo-β-lactamases, 93
  and *S. marcescens*, 93
  and *X. maltophilia*, 93
Metallo-β-lactamases
  clinical relevance, 93
  molecular structure, 93
  plasmid-mediated, 93
Methicillin-resistant *S. aureus*, 305, 422
Minocycline, in meningococcal disease, 15
Monoclonal antibodies
  against *B. melitensis*, 363
  against *E. coli* LPS, 100
  against *N. meningitidis*, 4, 7
  against *S. aureus*, 128
  against shigellae, 211
Mouse model
  cell-mediated response to *B. pertussis* infection 163
  endogenous septicaemia caused by *P. aeruginosa*, 141

host response to coagulase-negative staphylococci, 191
inflammatory response to "*G. suis*", 64
pathogenicity of co-aggregated oral bacteria, 183
Mycobacteria, *M. leprae*, diagnosis of infection, 298

Neisseria meningitidis
adherence, 7
antibodies, 4, 7, 9, 17
antigens, 3, 4, 9, 17
capsule, 3, 4, 9, 17
chemoprophylaxis of disease, 15
clinical features of disease, 11
epidemiology, 3
host responses to infection, 9
lipo-oligosaccharide, 3, 9, 17
management of disease, 11
monoclonal antibodies, 4, 7
outer-membrane proteins, 3, 4, 9, 17
pili, 3, 7
prognostic indicators in infection, 11
structure, 3
typing methods, 3, 4
vaccines, 17
Neurotoxins, 243
Nosocomial infections, 345
Nuclease, thermostable, of *S. aureus*, 128

Oral bacteria
effects of co-aggregation on pathogenicity, 183
extracellular products of viridans streptococci, 352
H. pylori in dental plaque, 338
in infective endocarditis, 179
in patients with Kawasaki disease, 352
production of hydrogen peroxide by oral streptococci, 429
transmission of *P. gingivalis*, 416
typing methods for *P. gingivalis*, 416

Papillomaviruses, human (HPV)
detection and typing, 33
Pasteurella
identification by API system, 78
Penicillin, in meningococcal disease, 15
Periodontitis, 416
Phage typing, of *S. aureus*, 305
Phagocytosis
co-aggregated oral bacteria by PMNLs, 183
E. coli by PMNLs in urine, 69
Pili
of *E. coli*, 371
of *N. meningitidis*, 3, 7
Plasmids
of *E. coli*, 371
metallo-β-lactamase of *B. fragilis*, 93
metallo-β-lactamase of *P. aeruginosa*, 93
multiresistance of *S. typhi*, 454
profile of *Edwardsiella* spp., 273
of *Yersinia* spp., 268
Plesiomonas shigelloides
shared virulence properties with shigellae, 211
virulence factors, 211
Polymerase chain reaction
detection of *H. pylori*, 338
detection and typing of human papillomaviruses, 33
diagnosis of candidosis, 233
diagnosis of hepatitis C virus infection, 323
diagnosis of leprosy, 298
fingerprinting microbes by random amplification of polymorphic DNA, 161
typing of *P. gingivalis*, 416
Polymorphonuclear leucocytes (PMNLs)
activation by *S. epidermidis*, 196
phagocytosis of co-aggregated oral bacteria, 183
phagocytosis and killing of *E. coli* in urine, 69
Porphyrin production, 262
Porphyromonas gingivalis
molecular typing methods, 416
transmission, 416

PROCEEDINGS OF THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND, Supplement 2 (Vol. 39 No. 1, July 1993)
Protease
of *A. fumigatus*, 393
of *P. aeruginosa*, 141
of *P. penneri*, 282
Proteinase, of *P. mirabilis*, 225
Proteins
exoproteins of *S. intermedius*, 429
heat shock protein gene of *C. albicans*, 233
outer-membrane, of *B. abortus*, 403
outer-membrane, of *E. coli*, 371
outer-membrane, of *N. meningitidis*, 3, 4, 9, 17
outer-membrane, of *P. aeruginosa*, 459
outer-membrane, of *Yersinia* spp., 268
protein A production by *S. aureus*, 422
whole-cell protein fingerprinting of *Aeromonas* spp., 107
Proteus
P. mirabilis, cleavage of IgG by proteinase, 225
P. mirabilis, in urinary infection, 225
P. penneri, haemolysin, 282
P. penneri, virulence factors, 282
Pseudomonas
P. aeruginosa, adherence, 459, 465
P. aeruginosa, in contact lens-associated keratitis, 1
P. aeruginosa, exotoxin A, 141
P. aeruginosa, IgG antibody response, 459, 465
P. aeruginosa, metallo-β-lactamase, 93
P. aeruginosa, outer-membrane proteins, 459
P. aeruginosa, plasmids, 93
P. aeruginosa, protease production, 141
P. aeruginosa, in septicaemia, 141
P. cepacia, immune response in cystic fibrosis, 39
P. cepacia, lipopolysaccharide antigens, 39
Psoriasis, 165
Puerperal infections, 165
Pyoderma, canine, 429
Pyrolysis mass spectrometry, 345

Radiolabelling, 233
Research and scientific publication, 85
Restriction analysis
characterisation of *S. intermedius* isolates, 429
in typing of human papillomaviruses, 33
typing of *P. gingivalis*, 416
Restriction fragment-length polymorphisms analysis of *Salmonella* serotype Enteritidis, 446
Rheumatic fever, streptococcal, 165
Ribotyping
of *P. gingivalis*, 416
Salmonella serotype Enteritidis, 446
Rifampicin
in meningococcal disease, 15
resistance, and *N. meningitidis*, 15
RNA, in serological diagnosis of hepatitis C virus, 323

Salmonellae
characterisation by genotypic methods, 446
insertion sequence IS*200*, 446, 454
S. typhi, antigens, 74
S. typhi, detection by co-agglutination assay, 74
S. typhi, multiresistance to antimicrobial agents, 454
S. typhi, plasmids, 454
serotype Enteritidis, 446
Scarlet fever, 165
SDS–PAGE
analysis of *Aeromonas* spp., 325
characterisation of *B. melitensis*, 363
exoproteins of *S. intermedius*, 429
outer-membrane proteins of *E. coli*, 371
whole-cell protein fingerprinting of *Aeronomas* spp., 107
Semliki Forest virus, pathogenesis *in vitro*, 26
Septicaemia
and fusobacteria, 246
P. aeruginosa, 141
Serology
diagnosis of verocytotoxigenic *E. coli* infection, 408

diagnosis of *Yersinia* spp. infection, 268
hepatitis C virus infection, 323
screening for hydatid disease, 48
Serotyping, *S. pyogenes*, 165
Serratia marcescens
carbapenem resistance, 93
metallo-β-lactamase, 93
Serum
antibodies against *P. cepacia* in cystic fibrosis, 39
bactericidal activity against *Edwardsiella* spp., 273
detection of hepatitis B virus, 473
detection of hepatitis C virus, 321, 323
detection of *S. typhi* infection, 74
enterotoxigenic bacteria in sudden infant death syndrome, 114
inhibition of adherence of *P. aeruginosa*, 465
Shigellae
S. dysenteriae, shared virulence properties with *P. shigelloides*, 211
S. flexneri, shared virulence properties with *P. shigelloides*, 211
Siderophore production, 218
Skin infections, strepococcal, 165
Sore throat, streptococcal, 165
Sputum, antibodies to *P. cepacia*, 39
Staphylococci
coagulase-negative, 191, 196, 204
host response within abscesses, 191
lipase production, 191
production of fatty acid modifying enzyme, 191
S. aureus, adherence, 422
S. aureus, enterotoxin, 114
S. aureus, fatty acid modifying enzyme, 191
S. aureus, lectin typing, 305
S. aureus, methicillin-resistant, 305, 422
S. aureus, methicillin-sensitive, 422
S. aureus, monoclonal antibodies, 128
S. aureus, phage typing, 305
S. aureus, phenotypic loss of protein A production, 422
S. aureus, rapid identification, 128
S. aureus, sensitivity to bactericidal lipids, 58
S. aureus, in sudden infant death syndrome, 114
S. aureus, survival in abscesses, 58
S. aureus, thermostable nuclease, 128
S. epidermidis, activation of PMNLs, 196
S. epidermidis, fatty acid modifying enzyme, 191
S. epidermidis, ultrastructure and antibiotic resistance, 204
S. intermedius, in canine pyoderma, 429
S. intermedius, characterisation 429
Streptococci
β-haemolytic, 440
biologically active extracellular products, 352
in infective endocarditis, 179
lectin typing, 440
oral, and Kawasaki disease, 352
oral, production of hydrogen peroxide, 429
S. bovis, adherence, 53
S. bovis, capsule, 53
S. bovis, glucan production, 53
S. mitis, co-aggregation with *A. viscosus*, 183
S. mitis, phagocytosis by PMNLs, 183
S. pyogenes, association with disease, 165
S. pyogenes, serotyping scheme, 165
viridans, 179, 352
Sudden infant death syndrome (SIDS)
role of enterotoxigenic bacteria, 114
Sulphadiazine, in meningococcal disease, 15
Sulphonamides, resistance and meningococci, 15

Taxonomy
of fusobacteria, 246
new *Brevibacterium* sp., 255
problems in, 401
Teicoplanin resistance, of *S. epidermidis*, 204
Tellurite
in selection of verocytotoxigenic *E. coli*, 155
Tissue culture *see* Cell culture
Toxins
of *C. botulinum*, 114, 243
intestinal, in sudden infant death syndrome, 114
of *P. penneri*, 282
therapeutic use of botulinum toxin, 243
see also Cytotoxins: Endotoxin: Enterotoxins: Exotoxins
Transferrin-binding properties, of *Haemophilus* spp., 218
Trichosporon beigelii, synergy with *Brevibacterium* sp., 255
Typhoid fever, diagnosis, 74

Urinary infection
cysteine-requiring *E. coli*, 382
cysteine-requiring *Klebsiella* strains, 382
P. mirabilis, 225
phagocytosis and killing of *E. coli* by PMNLs, 69

Vaccines
against *B. pertussis*, 163
against foot and mouth disease virus, 241
against influenza virus, 241
against malaria, 241
against *N. meningitidis*, 17
conjugate, 17
synthetic peptide, 241
Vancomycin resistance, of *S. epidermidis*, 204
Vibrio cholerae
immune response to outer-membrane antigens, 135
virulence factors, 310
Virulence factors
coagulase-negative staphylococci, 191
E. coli, 371
P. mirabilis, 225
P. penneri, 282
P. shigelloides, 211
S. dysenteriae, 211
S. flexneri, 211
V. cholerae, 310
Yersinia spp., 268
Vulvovaginitis, 165

Western blotting, 393
White piedra, 255

Xanthomonas maltophilia
carbapenem resistance, 93
metallo-β-lactamase, 93

Yersinia
outer-membrane proteins, 268
virulence plasmid, 268
Y. enterocolitica, diagnosis of infection, 268
Y. pseudotuberculosis, diagnosis of infection, 268

INDEX OF AUTHORS FOR VOLUME 39

ADAMS R A, *see* HARDIE *et al.*, 218
ALAM A N, *see* ALBERT *et al.*, 211
ALBERT M J, ANSARUZZAMAN M, QADRI F, HOSSAIN A, KIBRIYA A K M G, HAIDER K, NAHAR S, FARUQUE S M, ALAM A N. Characterisation of *Plesiomonas shigelloides* strains that share type-specific antigen with *Shigella flexneri* 6 and common group 1 antigen with *Shigella flexneri* spp. and *Shigella dysenteriae* 1, 211
ALLAKER R P, GARRETT N, KENT LOUISE, NOBLE W C, LLOYD D H. Characterisation of *Staphylococcus intermedius* isolates from canine pyoderma and from healthy carriers by SDS–PAGE of exoproteins, immunoblotting and restriction endonuclease digest analysis, 429
ANSARUZZAMAN M, *see* ALBERT *et al.*, 211

BAG PRASANTA K, *see* RAMAMURTHY *et al.*, 310
BENNETT K W, ELEY A. Fusobacteria: new taxonomy and related diseases, 246
BERNAL MARIA C, *see* GARCÍA *et al.*, 473
BEZARD G, *see* LIMET *et al.*, 403
BHADURI S, *see* FRATAMICO *et al.*, 371
BHATTACHARYA M K, *see* RAMAMURTHY *et al.*, 310
BHATTACHARYA S K, *see* RAMAMURTHY *et al.*, 310
BICKLEY J, OWEN R J, FRASER A G, POUNDER R E. Evaluation of the polymerase chain reaction for detecting the urease C gene of *Helicobacter pylori* in gastric biopsy samples and dental plaque, 338
BIFFIN ANNE H B, JONES M A, PALMER S R. Human hydatid disease: evaluation of an ELISA for diagnosis, population screening and monitoring of control programmes, 48
BLACK H S, *see* MCBRIDE *et al.*, 255
BORDUN A-M, *see* ROBINS-BROWNE *et al.*, 268
BOUCHARA J P, *see* MOUTAOUAKIL *et al.*, 393
BOWDEN R A, VERGER J M, GRAYON MAGGY, LIMET J N, DUBRAY G. Simultaneous expression of smooth and rough phase properties related to lipopolysaccharide in a strain of *Brucella melitensis*, 363
BRAKSTAD O G, MAELAND J A. Detection of *Staphylococcus aureus* with biotinylated monoclonal antibodies directed against staphylococcal TNase complexed to avidin-peroxidase in a rapid sandwich enzyme-linked immunofiltration assay (sELIFA), 128
BRAZIER J S, *see* MAGEE *et al.*, 345
BROWN D J, *see* OLSEN *et al.*, 446
BROWN P H, *see* NELSON *et al.*, 39
BRUMFITT W, *see* GARGAN *et al.*, 69
BUCHANAN R L, *see* FRATAMICO *et al.*, 371
BUTLER S L, *see* NELSON *et al.*, 39

CASTILLO ANA M, *see* GARCÍA-MENDOZA *et al.*, 434
CHAMBERLAIN N R, *see* XIONG *et al.*, 58
CHAPMAN P A, *see* SIDDONS AND CHAPMAN, 408
CHAPMAN P A, *see* ZADIK *et al.*, 155
CLARRIDGE J E, *see* MCBRIDE *et al.*, 255
CLOECKAERT A, *see* LIMET *et al.*, 403
COLLEE J G. A microbiologist's perspective, 87
COLMAN G, TANNA ASHA, EFSTRATIOU ANDROULLA, GAWORZEWSKA EWA T. The serotypes of *Streptococcus pyogenes* present in Britain during 1980–1990 and their association with disease, 165
CRAMPIN A C, MATTHEWS R C. Application of the polymerase chain reaction to the diagnosis of candidosis by amplification of an HSP 90 gene fragment, 233

DA COSTA C, *see* MAGEE *et al.*, 345
DE GRAAFF, *see* VAN STEENBERGEN *et al.*, 416
DE LA HIGUERA ANGUSTIAS, *see* GARCÍA-MENDOZA *et al.*, 434
DE LUIS BELEN, *see* GARCÍA *et al.*, 473
DE MIRANDA A B, *see* SANTOS *et al.*, 298
DEGRAVE W M, *see* SANTOS *et al.*, 298
DELAHOOKE T E S, *see* NELSON *et al.*, 100
DOUGLAS C W I, HEATH J, HAMPTON K K, PRESTON F E. Identity of viridans streptococci isolated from cases of infective endocarditis, 179
DUBRAY G, *see* BOWDEN *et al.*, 363
DUBRAY G, *see* LIMET *et al.*, 403
DUERDEN B I. Scientific publication—a cornerstone of the research cycle, 85
DUERDEN B I, *see* MAGEE *et al.*, 345

EFSTRATIOU ANDROULLA, *see* COLMAN *et al.*, 165
EHRET W, *see* LUPPA *et al.*, 262
ELEY A, *see* BENNETT AND ELEY, 246
ELLNER K M, *see* MCBRIDE *et al.*, 255
EZAKI T, *see* OHKUNI *et al.*, 352

FARUQUE S M, *see* ALBERT *et al.*, 211
FLEER A, *see* MARTÍNEZ-MARTÍNEZ *et al.*, 196
FOSTER T J, *see* POSTON *et al.*, 422
FRASER A G, *see* BICKLEY *et al.*, 338
FRATAMICO P M, BHADURI S, BUCHANAN R L. Studies on *Escherichia coli* serotype O157:H7 strains containing a 60-MDa plasmid and on 60-MDa plasmid-cured derivatives, 371
FURUYA N, HIRAKATA Y, TOMONO K, MATSUMOTO T, TATEDA K, KAKU M, YAMAGUCHI K. Mortality rates amongst mice with endogenous septicaemia caused by *Pseudomonas aeruginosa* isolates from various clinical sources, 141

GANT V A, WARNES G, PHILLIPS I, SAVIDGE G F. The application of flow cytometry to the study of bacterial responses to antibiotics, 147
GARCÍA F, QUIROS EUGENIA, BERNAL MARIA C, DE LUIS BELEN, LEYVA ANA, PIÉDROLA G, MAROTO MARIA C. Serum hepatitis B virus DNA detection with S- and C-region-directed probes, 473
GARCÍA-MENDOZA A, LIÉBANA J, CASTILLO ANA M, DE LA HIGUERA ANGUSTIAS, PIÉDROLA G. Evaluation of the capacity of oral streptococci to produce hydrogen peroxide, 434
GARGAN R A, SMITH G W, HAMILTON-MILLER J M T, BRUMFITT W. Effect of bacterial products including endotoxin on neutrophil function in infected urine, 69
GARRETT N, *see* ALLAKER *et al.*, 429
GASSMANN G, *see* KAISER *et al.*, 290
GAWORZEWSKA EWA T, *see* COLMAN *et al.*, 165
GE S, *see* XIONG *et al.*, 58
GIBERT I, *see* THRELFALL *et al.*, 454
GLANCEY G R, *see* POSTON *et al.*, 422
GOVAN J R W, *see* NELSON *et al.*, 39
GRAYON MAGGY, *see* BOWDEN *et al.*, 363
GREENING A P, *see* NELSON *et al.*, 39
GREENWOOD D, *see* SANYAL AND GREENWOOD, 204
GRIFFITHS, A, *see* MAGEE *et al.*, 345

HAIDER K, *see* ALBERT *et al.*, 211
HAMBLETON P. Therapeutic application of botulinum toxin, 243
HAMILTON-MILLER J M T. A possible pitfall in the identification of *Pasteurella* spp. with the API system, 78
HAMILTON-MILLER J M T, *see* GARGAN *et al.*, 69
HAMPTON K K, *see* DOUGLAS *et al.*, 179
HARADA K, *see* OHKUNI *et al.*, 352
HARDIE K R, ADAMS R A, TOWNER K J. Transferrin-binding ability of invasive and commensal isolates of *Haemophilus* spp., 218
HART C A, ROGERS T R F. Meningococcal disease, 3
HASHIMOTO Y, *see* OHKUNI *et al.*, 352
HAY J, *see* SEAL AND HAY, 1
HEATH J, *see* DOUGLAS *et al.*, 179
HILL D W, *see* MAGEE *et al.*, 345
HIRAKATA Y, *see* FURUYA *et al.*, 141

HOGAN T, *see* POSTON *et al.*, 422
HOSEIN I K, *see* MAGEE *et al.*, 345
HOSSAIN A, *see* ALBERT *et al.*, 211

IGARASHI H, *see* OHKUNI *et al.*, 352
IKEDA T, *see* OCHIAI *et al.*, 183
IMADA Y, *see* OHKUNI *et al.*, 352

JACOB K, *see* LUPPA *et al.*, 262
JACOBS J A, *see* KELLENS *et al.*, 440
JAKOB R. Pathogenesis of alphavirus infection as demonstrated by infection of ECV 304 transformed human umbilical vein capillary endothelial cells with Semliki Forest virus, 26
JARLØV J O, ROSDAHL V T, YEO M, MARPLES R R. Lectin typing of methicillin-resistant *Staphylococcus aureus* from Singapore, England and Wales, and Denmark, 305
JONES M A, *see* BIFFIN *et al.*, 48

KAISER R, RASIAH C, GASSMANN G, VOGT A, LÜCKING C H. Intrathecal antibody synthesis in Lyme neuroborreliosis: use of recombinant p41 and a 14-kDa flagellin fragment in ELISA, 290
KAKU, M, *see* FURUYA *et al.*, 141
KAMINO Y, *see* OCHIAI *et al.*, 183
KAPRAL F A, *see* LONG AND KAPRAL, 191
KAPRAL F A, *see* XIONG *et al.*, 58
KARASAWA TADAHIRO, *see* RAMAMURTHY *et al.*, 310
KARIKS S, *see* MURRELL *et al.*, 114
KEANE C T, *see* XIA *et al.*, 334
KELLENS J T C, JACOBS J A, PEUMANS W J, STOBBERINGH ELLEN E. The agglutination of β-haemolytic streptococci by lectins, 440
KENT LOUISE, *see* ALLAKER *et al.*, 429
KERR M A, *see* LOOMES *et al.*, 225
KHAN H M, *see* MUKHERJEE *et al.*, 74
KIBRIYA A K M G, *see* ALBERT *et al.*, 211
KOTANI S, *see* OHKUNI *et al.*, 352
KURAZONO HISAO, *see* RAMAMURTHY *et al.*, 310
KURITA-OCHIAI T, *see* OCHIAI *et al.*, 183

LATGÉ J P, *see* MOUTAOUAKIL *et al.*, 393
LEYVA ANA, *see* GARCÍA *et al.*, 473
LIÉBANA J, *see* GARCÍA-MENDOZA *et al.*, 434
LIMET J N, CLOECKAERT A, BEZARD G, VAN BROECK J, DUBRAY G. Antibody response to the 89-kDa outer-membrane protein of brucella in bovine brucellosis, 403
LIMET J N, *see* BOWDEN *et al.*, 363
LLOYD D H, *see* ALLAKER *et al.*, 429
LONG J P, KAPRAL F A. Host response to coagulase-negative staphylococci in abscesses induced within mice, 191
LOOMES L M, KERR M A, SENIOR B W. The cleavage of immunoglobulin G *in vitro* and *in vivo* by a proteinase secreted by the urinary tract pathogen *Proteus mirabilis*, 225
LÜCKING C H, *see* KAISER *et al.*, 290
LUPPA P, JACOB K, EHRET W. The production of porphyrins from δ-aminolaevulinic acid by *Haemophilus parainfluenzae*, 262

MCBRIDE M E, ELLNER K M, BLACK H S, CLARRIDGE J E, WOLF J E. A new *Brevibacterium* sp. isolated from infected genital hair of patients with white piedra, 255
MCIVER C J, TAPSALL J W. Further studies of clinical isolates of cysteine-requiring *Escherichia coli* and *Klebsiella* and possible mechanisms for their selection *in vivo*, 382
MAELAND J A, *see* BRAKSTAD AND MAELAND, 128
MAGEE J T. Forsaking the tome—a worms' eye view of taxonomy, 401
MAGEE J T, BRAZIER J S, HOSEIN I K, RIBEIRO C D, HILL D W, GRIFFITHS A, DA COSTA C, SINCLAIR A J, DUERDEN B I. An investigation of a nosocomial outbreak of *Clostridium difficile* by pyrolysis mass spectrometry, 345
MALIK ABIDA, *see* MUKHERJEE *et al.*, 74
MALIK A, *see* MUKHERJEE *et al.*, 74
MAROTO MARIA C, *see* GARCÍA *et al.*, 473
MARPLES R R, *see* JARLØV *et al.*, 305
MARTÍNEZ-MARTÍNEZ L, TIMMERMAN C P, FLEER A, VERHOEF J. Chemiluminescence of human polymorphonuclear leucocytes after stimulation with whole cells and cell-wall components of *Staphylococcus epidermidis*, 196
MASCHERA B, *see* PIZZIGHELLA *et al.*, 33
MATSUMOTO T, *see* FURUYA *et al.*, 141
MATTHEWS R C. PCR fingerprinting microbes by random application of polymorphic DNA, 161
MATTHEWS R C, *see* CRAMPIN AND MATTHEWS, 233
MENARD C, *see* VAN STEENBERGEN *et al.*, 416
MENDES E N, *see* MOURA *et al.*, 64
MILLER MARCIA A, *see* REGER *et al.*, 273
MILLERSHIP SALLY E, WANT SUSAN V. Characterisation of strains of *Aeromonas* spp. by phenotype and whole-cell protein fingerprint, 107
MILLERSHIP SALLY, *see* MULLA AND MILLERSHIP, 325
MILLS K H G, REDHEAD K. Cellular immunity in pertussis, 163
MIZUSE M, *see* OHKUNI *et al.*, 352
MOCKLER DIANNE F, *see* REGER *et al.*, 273
MONOD M, *see* MOUTAOUAKIL *et al.*, 393
MORRIN MARY, REEN D J. Inhibition of the adherence of *Pseudomonas aeruginosa* to epithelial cells by IgG subclass antibodies, 465
MORRIN MARY, REEN D J. Role of IgG subclass response to outer-membrane proteins in inhibiting adhesion of *Pseudomonas aeruginosa* to epithelial cells, 459
MOURA SILVIA B, QUEIROZ DULCIENE M M, MENDES E N, NOGUEIRA ANA M M F, ROCHA G A. The inflammatory response of the gastric mucosa of mice experimentally infected with "*Gastrospirillum suis*", 64
MOUTAOUAKIL M, MONOD M, PRÉVOST M C, BOUCHARA J P, PARIS S, LATGÉ J P. Identification of the 33-kDa alkaline protease of *Aspergillus fumigatus in vitro* and *in vivo*, 393
MOUTON C, *see* VAN STEENBERGEN *et al.*, 416
MUKHERJEE C, MALIK ABIDA, KHAN H M, MALIK A. Rapid diagnosis of typhoid fever by co-agglutination in an Indian hospital, 74
MULLA ROHINTON, MILLERSHIP SALLY. Typing of *Aeromonas* spp. by numerical analysis of immunoblotted SDS–PAGE gels, 325
MURRELL W G, STEWART BETTY J, O'NEILL CATA, SIARAKAS S, KARIKS S. Enterotoxigenic bacteria in the sudden infant death syndrome, 114
MUTIMER D. Hepatitis C virus infection—prognosis and treatment, 321

NAHAR S, *see* ALBERT *et al.*, 211
NAIR G BALAKRISH, *see* RAMAMURTHY *et al.*, 310
NELSON D, DELAHOOKE T E S, POXTON I R. Influence of subinhibitory levels of antibiotics on expression of *Escherichia coli* lipopolysaccharide and binding of anti-lipopolysaccharide monoclonal antibodies, 100
NELSON J W, BUTLER S L, BROWN P H, GREENING A P, GOVAN J R W. Serum IgG and sputum IgA antibody to core lioppolysaccharide antigen from *Pseudomonas cepacia* in patients with cystic fibrosis, 39
NOBLE W C, *see* ALLAKER *et al.*, 429
NOGUEIRA ANA M M F, *see* MOURA *et al.*, 64

OCHIAI K, KURITA-OCHIAI T, KAMINO Y, IKEDA T. Effect of co-aggregation on the pathogenicity of oral bacteria, 183
OHKAWA S, *see* OHKUNI *et al.*, 352
OHKUNI H, TODOME YUKO, MIZUSE M, OHTANI N, SUZUKI H, IGARASHI H, HASHIMOTO Y, EZAKI T, HARADA K, IMADA Y, OHKAWA S, KOTANI S. Biologically active extracellular products of oral viridans streptococci and the aetiology of Kawasaki disease, 352
OHTANI N, *see* OHKUNI *et al.*, 352
OLSEN J E, SKOV MARIANNE N, THRELFALL E J, BROWN D J. Clonal lines of *Salmonella enterica* serotype Enteritidis documented by IS*200*-, ribo-, pulsed-field gel electrophoresis and RFLP typing, 446
O'MORAIN C A, *see* XIA *et al.*, 334
O'NEILL CATA, *see* MURRELL *et al.*, 114
OREFICI GRAZIELLA, *see* VON HUNOLSTEIN *et al.*, 53
OWEN R J, *see* BICKLEY *et al.*, 338

PAL AMIT, *see* RAMAMURTHY *et al.*, 310
PALMER S R, *see* BIFFIN *et al.*, 48
PALÚ G, *see* PIZZIGHELLA *et al.*, 33
PARIS S, *see* MOUTAOUAKIL *et al.*, 393
PAYNE D J. Metallo-β-lactamases—a new therapeutic challenge, 93
PEUMANS W J, *see* KELLENS *et al.*, 440
PHILLIPS I, *see* GANT *et al.*, 147
PIACENTINI I, *see* PIZZIGHELLA *et al.*, 33
PIÉDROLA G, *see* GARCÍA *et al.*, 473
PIÉDROLA G, *see* GARCIA-MENDOZA *et al.*, 434
PIZZIGHELLA S, RASSU M, PIACENTINI I, MASCHERA B, PALU G. Polymerase chain reaction amplification and restriction enzyme typing as an accurate and simple way to detect and identify human papillomaviruses, 33
POSTON S M, GLANCEY G R, WYATT J E, HOGAN T, FOSTER T J. Co-elimination of *mec* and *spa* genes in *Staphylococcus aureus* and the effect of *agr* and protein A production on bacterial adherence to cell monolayers, 422
POUNDER R E, *see* BICKLEY *et al.*, 338
POXTON I R, *see* NELSON *et al.*, 100
PRESTON F E, *see* DOUGLAS *et al.*, 179
PRÉVOST M C, *see* MOUTAOUAKIL *et al.*, 393

QADRI F, *see* ALBERT *et al.*, 211
QUEIROZ DULCIENE M M, *see* MOURA *et al.*, 64
QUIROS EUGENIA, *see* GARCÍA *et al.*, 473

RAMAMURTHY T, BAG PRASANTA K, PAL AMIT, BHATTACHARYA S K, BHATTACHARYA M K, SHIMADA TOSHIO, TAKEDA TAE, KARASAWA TADAHIRO KURAZONO HISAO, TAKEDA YOSHIFUMI, NAIR G BALAKRISH. Virulence patterns of *Vibrio cholerae* non-O1 strains isolated from hospitalised patients with acute diarrhoea in Calcutta, India, 310
RASIAH C, *see* KAISER *et al.*, 290
RASSU M, *see* PIZZIGHELLA *et al.*, 33
REDHEAD K, *see* MILLS AND REDHEAD, 163
REEN D J, *see* MORRIN AND REEN, 459, 465
REGER P J, MOCKLER DIANNE F, MILLER MARCIA A. Comparison of antimicrobial susceptibility, β-lactamase production, plasmid analysis and serum bactericidal activity in *Edwardsiella tarda*, *E. ictaluri* and *E. hoshinae*, 273
RIBEIRO C D, *see* MAGEE *et al.*, 345
RICCI M LUISA, *see* VON HUNOLSTEIN *et al.*, 53
ROBINS-BROWNE R M, BORDUN A-M, SLEE K J. Serological response of sheep to plasmid-encoded proteins of *Yersinia* species following natural infection with *Y. enterocolitica* and *Y. pseudotuberculosis*, 268
ROCHA G A, *see* MOURA *et al.*, 64
ROGERS T R F, *see* HART AND ROGERS, 3
ROSDAHL V T, *see* JARLØV *et al.*, 305
ROWE B, *see* THRELFALL *et al.*, 454

SAKURAI Y, SUZUKI H, TERADA E. Purification and characterisation of haemagglutinin from *Bordetella bronchiseptica*, 388
SANTOS A R, DE MIRANDA A B, SARNO E N, SUFFYS P N, DEGRAVE W M. Use of PCR-mediated amplification of *Mycobacterium leprae* DNA in different types of clinical samples for the diagnosis of leprosy, 298
SANYAL D, GREENWOOD D. An electronmicroscope study of glycopeptide antibiotic-resistant strains of *Staphylococcus epidermidis*, 204
SARNO E N, *see* SANTOS *et al.*, 298
SAVIDGE G F, *see* GANT *et al.*, 147
SCIORTINO CARMEN V. Human immune response to the 18-kDa outer-membrane antigen of *Vibrio cholerae*, 135
SEAL D V, HAY J. The microbiologist as a contact lens wearer, 1
SENIOR B W. The production of HlyA toxin by *Proteus penneri* strains, 282
SENIOR B W, *see* LOOMES *et al.*, 225
SESARDIC DOROTHEA. Synthetic peptide vaccines, 241
SHIMADA TOSHIO, *see* RAMAMURTHY *et al.*, 310
SIARAKAS S, *see* MURRELL *et al.*, 114
SIDDONS C A, CHAPMAN P A. Detection of serum and faecal antibodies in haemorrhagic colitis caused by *Escherichia coli*, 408
SIDDONS C A, *see* ZADIK *et al.*, 155
SINCLAIR A J, *see* MAGEE *et al.*, 345
SKIDMORE S. Hepatitis C virus—epidemiology and serological diagnosis, 323
SKOV MARIANNE N, *see* OLSEN *et al.*, 446
SLEEK, J, *see* ROBINS-BROWNE *et al.*, 268
SMITH G W, *see* GARGAN *et al.*, 69
STEWART BETTY J, *see* MURRELL *et al.*, 114
STOBBERINGH ELLEN E, *see* KELLENS *et al.*, 440
SUFFYS P N, *see* SANTOS *et al.*, 298
SUZUKI H, *see* OHKUNI *et al.*, 352
SUZUKI H, *see* SAKURAI *et al.*, 388

TAKEDA TAE, *see* RAMAMURTHY *et al.*, 310
TAKEDA YOSHIFUMI, *see* RAMAMURTHY *et al.*, 310
TANNA ASHA, *see* COLMAN *et al.*, 165
TAPSALL J W, *see* MCIVER AND TAPSALL, 382
TATEDA K, *see* FURUYA *et al.*, 141
TERADA E, *see* SAKURAI *et al.*, 388
THRELFALL E J, TORRE E, WARD L R, ROWE B, GIBERT I. Insertion sequence IS*200* can differentiate drug-resistant and drug-sensitive *Salmonella typhi* of Vi-phage types E1 and M1, 454
THRELFALL E J, *see* OLSEN *et al.*, 446
TIJHOF C J, *see* VAN STEENBERGEN *et al.*, 416
TIMMERMAN C P, *see* MARTÍNEZ-MARTÍNEZ *et al.*, 196
TODOME YUKO, *see* OHKUNI *et al.*, 352
TOMONO K, *see* FURUYA *et al.*, 141
TORRE E, *see* THRELFALL *et al.*, 454
TOWNER K J, *see* HARDIE *et al.*, 218

VAN BROECK J, *see* LIMET *et al.*, 403
VAN STEENBERGEN T J M, MENARD C, TIJHOF C J, MOUTON C, DE GRAAFF J. Comparison of three molecular typing methods in studies of transmission of *Porphyromonas gingivalis*, 416
VERGER J M, *see* BOWDEN *et al.*, 363
VERHOEF J, *see* MARTÍNEZ-MARTÍNEZ *et al.*, 196
VOGT A, *see* KAISER *et al.*, 290
VON HUNOLSTEIN CHRISTINA, RICCI M LUISA, OREFICI GRAZIELLA. Adherence of glucan-positive and glucan-negative strains of *Streptococcus bovis* to human epithelial cells, 53

WANT SUSAN V, *see* MILLERSHIP AND WANT, 107
WARD L R, *see* THRELFALL *et al.*, 454
WARNES G, *see* GANT *et al.*, 147
WOLF J E, *see* MCBRIDE *et al.*, 255
WYATT J E, *see* POSTON *et al.*, 422

XIA H X, KEANE C T, O'MORAIN C A. Determination of the optimal transport system for *Helicobacter pylori* cultures, 334
XIONG ZHUO, GE S, CHAMBERLAIN N R, KAPRAL F A. Growth cycle-induced changes in sensitivity of *Staphylococcus aureus* to bactericidal lipids from abscesses, 58

YAMAGUCHI K, *see* FURUYA *et al.*, 141
YEO M, *see* JARLØV *et al.*, 305

ZADIK P M, CHAPMAN P A, SIDDONS C A. Use of tellurite for the selection of verocytotoxigenic *Escherichia coli*, 155